Joint statement in support of hepatitis C human challenge studies
- PMID: 37742699
- DOI: 10.1016/S2468-1253(23)00314-X
Joint statement in support of hepatitis C human challenge studies
Conflict of interest statement
The views expressed above are those of the individual signatories, and do not necessarily represent an endorsement by their institutions. JDE and JM are employees of 1Day Sooner, which organised this letter and has received funding from Open Philanthropy in support of its hepatitis C-related work. MJB has received research grants from AbbVie, Gilead, and Cepheid. JJF has received research grants from AbbVie and Gilead, and consulting payments from AbbVie, Gilead, Arbutus, GSK, Roche, Vir, and Janssen. JVG's organisation has received payments from AbbVie, Gilead, and Cepheid, and JVG has participated in data safety monitoring boards or advisory boards for AbbVie and Gilead. ALC and DLT are professors at The Johns Hopkins University, which has received funding from the US National Institutes of Health (NIH; 5U19AI159822-03) for hepatitis C vaccine development; ALC is a principal investigator on several subprojects. EB is a principal investigator on another subproject under the same NIH grant. DLT owns stock in Excision Bio, has received consulting payments from Excision Bio and Everys Bio and payment from Merck for participation on an advisory board. CW has received consulting fees from Eli Lilly & Company, Cardialen, and Research Triangle Institute International. HJA, TJL, and NHS declared no competing interests.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical